ArticleBMC infectious diseases2026
Diagnostic accuracy of the Fujifilm SILVAMP TB LAM II (FujiLAM II) assay for the diagnosis of childhood tuberculosis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPoint-of-care tests (POCTs) are urgently needed to improve tuberculosis (TB) diagnosis in children. This study evaluated the diagnostic accuracy of the Fujifilm SILVAMP TB LAM II (FujiLAM II) assay for childhood TB diagnosis.
methodsSpot urine samples were collected from children with TB (either bacteriologically confirmed or clinically diagnosed) and from healthy controls, then tested using FujiLAM II. Sensitivity was assessed against microbiological and clinical reference standards, while specificity was determined against healthy controls.
resultsOf 137 participants, 87 had TB and 50 were controls. FujiLAM II showed overall sensitivity of 17.2%, higher in bacteriologically confirmed cases (36.8%) than in clinically diagnosed cases (11.8%). Sensitivity was better in children under five (27.9%), HIV-positive children (25.0%), and underweight or stunted children (24.0%). Specificity was 100%. In the subgroup of 66 children tested with both assays, detection rates did not differ significantly (28.8% vs. 22.7%). When results from either test were considered positive, the detection rate increased to 40.9%, representing a 12.1% improvement over Xpert Ultra alone.
conclusionFujiLAM II shows suboptimal sensitivity for childhood TB diagnosis, with better sensitivity in children under five years, HIV-positive, or malnourished, and may add value to current diagnostic algorithms.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.